Clinical Standardization

Inpatient Hospitalist-performed Procedural Anticoagulation Guideline

Updated: February 8, 2023

Anticoagulation Recommendations and Laboratory Cutoffs for Hospitalist Percutaneous Procedures								
single antiplatele procedure can be and thrombosis n guide, but is not n DVT Prophylaxis and thoracentesis	t agent or single ant e safely performed w nust be carefully bal meant to replace clir s: DVT prophylaxis o s.	does not need to be held for low b	t risk factors for t has other risk e helpful. As with leeding risk prod	factors, then the ris	g, the sk of bleeding puld serve as a			
General Manage	Patient-Specific Thrombotic Risk*	eeding and Thrombotic Risk Fac	Low					
	Patient-Specific Bleeding Risk**	High***	Low	High***	Low			
Warfarin		Perform procedure with INR 2- 3, patient discussion of risks/benefits, if holding warfarin, strongly consider bridging	Perform procedure with INR 2-3	Consider warfarin hold 2 days prior to procedure or reversal if urgent	Perform procedure with INR 2-3			
Direct Oral Anticoagulants		Patient discussion of risks/benfits, consider holding no more than 24 hrs vs performing procedure on DOAC depending on discussion and specific risk factors for bleeding/clotting	Continue DOAC	Consider 24-48 hr hold depending on individual risk factors.	Continue DOAC			
Aspirin Plavix		Continue						

🚺 Corewell Health

*Thrombotic Risk: Thrombotic risk is considered high for patients with elevated CHADSVASC scores (>5), thrombosis within 3 months, stroke or TIA within 6 months, antiphospholipid antibody syndrome, recurrent VTE, multiple thrombophilic conditions, mitral or tricuspid valve prosthesis, mechanical valves of any kind

**Bleeding Risk: Bleeding risk is considered high for patient on antiplatelet agents in addition to anticoagulation, especially triple therapy, significant bleeding within the last 3 months, prior bleeding with a similar procedure, HAS-BLED score >3

***For patients with high bleeding risks and in whom anticoagulation cannot be held, consider interventional pulmonology consultation for thoracentesis. Given some evidence of decreased tortuosity of the subcostal arteries further from midline, consideration for a more lateral puncture site (closer to the mid-axillary line rather than the vertebrae) for thoracentesis should be strongly considered in these patients.

PT/INR monitoring not routinely	Platelet monitoring not routinely	In cirrhosis, no INR cutoff exists, consensus guidelines recommend platelet counts be		
required, if on warfarin, INR target is usually	recommended, consider transfusion if	> 20k, fibrinogen >100.		
2-3	<20k in patients without cirrhosis			

Clinical Pathway Summary

CLINICAL PATHWAY NAME: Inpatient Hospitalist-performed Procedural Anticoagulation Management Guideline

PATIENT POPULATION AND DIAGNOSIS:

- Inpatients who have a paracentesis or thoracentesis performed using Point of Care Ultrasound by Hospitalist provider
- Diagnoses of Ascites or Pleural Effusion with indications for procedure

APPLICABLE TO: Butterworth Hospital

BRIEF DESCRIPTION:

- Algorithms and guidelines for Hospitalist-performed procedures, to standardize clinical pathways and communicate best practices.
- Anticoagulation guidelines related to Paracentesis and Thoracentesis procedures.
- Refer to Ascites and Pleural Effusion Pathways: <u>Diagnostic Approach to Ascites Paracentesis</u>; <u>Diagnostic Approach to Pleural Effusion - Thoracentesis</u>



OPTIMIZED EPIC ELEMENTS (if applicable): Orders: Paracentesis Performed by Hospitalist, Thoracentesis Performed by Hospitalist

IMPLEMENTATION DATE: 12/28/2022

LAST REVISED: 2/8/2023

Clinical Pathways Clinical Approach

TREATMENT AND MANAGEMENT:

- For low-bleeding-risk procedures, such as paracentesis and thoracentesis, holding anticoagulation or antiplatelet agents is not routinely recommended, especially if these agents are needed for highthrombotic risk conditions.
- If patients have high individual bleeding risk and are on multiple agents, then risks and benefits of holding anticoagulation should be weighed against that patient's individual thrombotic risk.

Pathway Information

OWNERS: Dr. Jeremy Gentile, Dr. Cheryl Peavler

CONTRIBUTOR(S): Ascites – Hannah Bray and Andrew Shriener. Pleural Effusion and Anticoagulation Guidelines – John Egan and Fergus Peacock

EXPERT IMPROVEMENT TEAM (EIT): Hospitalist Quality EIT

CLINICAL PRACTICE COUNCIL (CPC): Acute Health CPC

CPC APPROVAL DATE: 2/7/2023

OTHER TEAM(S) IMPACTED: ED, Specialty Health

References:

References:

1. Patel, I. J., Rahim, S., Davidson, J. C., Hanks, S. E., Tam, A. L., Walker, T. G., Wilkins, L. R., Sarode, R., & amp; Weinberg, I. (2019). Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—part II: Recommendations. Journal of Vascular and Interventional Radiology, 30(8). https://doi.org/10.1016/j.jvir.2019.04.017

2. Hibbert R.M. Atwell T.D. Lekah A. et al. Safety of ultrasound-guided thoracentesis in patients with abnormal preprocedural coagulation parameters. Chest. 2013; 144: 456-463

3. Orlandi E. Citterio C. Seghini P. Di Nunzio C. Mordenti P. Cavanna L. Thoracentesis in advanced cancer patients with severe thrombocytopenia: ultrasound guide improves safety and reduces bleeding risk. Clin Respir J. 2018; 12: 1747-1752

 Patel M.D. Joshi S.D. Abnormal preprocedural international normalized ratio and platelet counts are not associated with increased bleeding complications after ultrasound-guided thoracentesis. AJR Am J Roentgenol. 2011; 197: W164-W168
Bleeding rate for ultrasound-guided paracentesis in thrombocytopenic patients. J Ultrasound Med. 2015; 34: 1833-1838